Sal-like protein 4 (SALL4)

Similar documents
Assessment Run GATA3

Assessment Run NKX3.1 (NKX3.1)

Estrogen receptor (ER)

Thyroid transcription factor-1 (TTF1) Assessment run

SMH (Myosin, smooth muscle heavy chain)

Lung Anaplastic Lymphoma Kinase (lu-alk)

Carcinoembryonic antigen (CEA)

Epithelial cell-cell adhesion molecule (Ep-CAM)

Cytokeratin 19 (CK19)

Assessment Run

Estrogen receptor (ER)

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Assessment Run CK19

Estrogen receptor (ER)

Assessment Run B HER2 IHC

Assessment Run B HER2 IHC

Assessment Run C1 2017

Assessment Run C3 2018

Breast cancer: Antibody selection, protocol optimzation controls and EQA

HER2 ISH (BRISH or FISH)

Optimization of antibodies, selection, protocols and controls Breast tumours

IHC Stainer platforms. Overview, pros and cons

Assessment Run B HER-2

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

10 years of NordiQC Why are 30% of labs still getting it wrong?

NordiQC - update

External Quality Assessment of melanocytic marker analyses NordiQC experience

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

Nordic Immunohistochemical Quality Control

Image analysis in IHC overview, considerations and applications

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

External Quality Assessment of Breast Marker Analysis. NordiQC data

NordiQC External Quality Assurance in Immunohistochemistry

Immunohistochemical principles The technical test approach. Pre-analytical parametres

Supplementary Online Content

IDH1 R132H/ATRX Immunohistochemical validation

HPV/p16 Analyte Control

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors

Supplementary Appendix

The impact of proficiency testing on lab immunoassays

HistoCyte Laboratories Ltd

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Supplemental Information. Nodal Signaling Regulates Germ Cell. Development and Establishment of Seminiferous. Cords in the Human Fetal Testis

Tinh hoàn

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

Intratubular Germ Cell Neoplasia of the Testis

Testis/ovary germ cell tumor tissue array, 48 cases, 96 samples

Note: The cause of testicular neoplasms remains unknown

Male Genital Cancers in the US in Frequency of Types

Classification of the unknown primary tumour: the primary IHC panel

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Single and Multiplex Immunohistochemistry

Results you can trust

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

Product Introduction

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Diagnostic IHC in lung and pleura pathology

The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia

Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1

Testicular Germ Cell Tumors; A Simplistic Approach

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Immunotherapy in NSCLC Pathologist role

Workflow. Connecting the Pieces For Total Patient Care

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

Milestones in Her 2 Testing

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy

Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-

VENTANA PD-L1 (SP142) Assay

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

In Situ Hybridization: Market Strategies and Forecasts, US,

Immunocytochemistry. Run 106/35. Also In This Issue IN THIS ISSUE

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

Anti-PD-L1 antibody [28-8] ab205921

Immunohistochemistry. Potential and challenges To be or not to be

TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma

PD-L1 Analyte Control DR

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK)

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Interpretation Guide. Product Name: ALK Cell Line Analyte Control Product Codes: ALK2/CS and ALK2/CB. Page 1 of 9

The PAX8 gene is a member of the paired-box family of

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

Product Datasheet. EMMPRIN/CD147 Antibody (MEM-M6/1) NB Unit Size: 0.1 mg. Store at 4C. Do not freeze. Publications: 2

SUPPLEMENTARY MATERIAL. Sample preparation for light microscopy

Supplementary Online Content

SUPPLEMENTAL INFORMATION FOR. PAX7 expression defines germline stem cells in the adult testis

Morphologic Aspects Aspects

NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

Transcription:

Assessment Run 43 205 Sal-like protein 4 (SALL4) The slide to be stained for SALL4 comprised:. Appendix, 2. Testis, 3. Renal clear cell carcinoma, 4. Seminoma, 5. Intratubular germ cell neoplasia (IGCN), 6. Embryonal carcinoma All tissues were fixed in 0% neutral buffered formalin. Criteria for assessing a SALL4 staining as optimal included: An at least weak to moderate nuclear staining reaction of the majority of spermatogonia lining the basement membrane in seminiferous tubules of the normal testis. A moderate to strong nuclear staining reaction of virtually all neoplastic cells in the IGCN, seminoma and embryonal carcinoma. No staining of neoplastic cells in the renal clear cell carcinoma. No staining of any cells in the appendix. Participation Number of laboratories registered for SYP, run 43 53 Number of laboratories returning slides 5 (96%) 5 laboratories participated in this assessment. 50 (98%) of these achieved a sufficient mark (optimal or good). Table summarizes antibodies (Abs) used and assessment marks (see page 2). The cause of insufficient staining was: - Too high concentration of the primary antibody Performance history This was the first NordiQC assessment of SALL4. Table 2 shows the proportion of sufficient results. It is very encouraging that the proportion of sufficient results was so high despite SALL4 is a relatively new marker. Table 2. Proportion of sufficient results for SALL4 in the first NordiQC run Run 43 205 Participants, n= 5 Sufficient results 98% Conclusion The was found to be a very robust and recommendable antibody for demonstration of SALL4. In concentrated format, optimal results could be obtained on all three main IHC systems and in general a high pass rate was observed. HIER and careful calibration of the primary antibody were the most important prerequisites for optimal staining results. Correponding RTU systems of the (Ventana/Cell Marque and BioCare) also provided a high pass rate and proportion of optimal results. Normal testis is recommendable as positive tissue control for SALL4. The majority of spermatogonia must show an at least weak to moderate nuclear staining reaction. Appendix can be used as negative tissue control. No staining reaction should be seen. Nordic Immunohistochemical Quality Control, SALL4 run 43 205 Page of 5

Table. Antibodies and assessment marks for SALL4, run 43 Concentrated antibodies: Ready-To-Use Abs: 4 6 2 0 2 3 n Vendor Optimal Good Borderline Poor Abnova Biocare Biosite Cell Marque Master Diagnostica Novus Biological Sigma Aldrich Abcam Beijingzhongsan Novus Biologicals Comments In this first run of external quality assessment of SALL4, a pass rate of 98% was observed. Only of 5 laboratories obtained an insufficient mark due to a poor signal-to-noise ratio. This was most likely caused Nordic Immunohistochemical Quality Control, SALL4 run 43 205 Page 2 of 5 Suff. Suff. OPS 2 22 8 0 98% 97% 8 Ventana/Cell Marque 5 3 0 0 00% 00% CM385 MAD-000572QD MAB-069 PM384 7 Cell Marque 5 2 0 0 00% 00% 2 Master Diagnostica 0 0 - - 2 Maixin 2 0 0 0 - - Biocare 0 0 0 - - Total 5 36 4 0 - Proportion 7% 27% 2% 0 98% ) Proportion of sufficient stains (optimal or good) 2) Proportion of sufficient stains with optimal protocol settings only, see below. Detailed analysis of SALL4, Run 43 The following protocol parameters were central to obtain an optimal staining: Concentrated antibodies : Protocols with optimal results were all based on heat induced epitope retrieval (HIER) using either Tris-EDTA/EGTA ph 9 (/2)*, Target Retrieval Solution ph 9 (3-in-) (Dako) (4/5), Bond Epitope Retrieval Solution 2 (Bond, Leica) (2/3), Bond Epitope Retrieval Solution (Bond, Leica) (/2) or Cell Conditioning (BenchMark, Ventana)(4/7) as retrieval buffer. The mab was typically diluted in the range of :30 :800 depending on the total sensitivity of the protocol employed. Using these protocol settings 29 out of 30 (97%) laboratories produced a sufficient staining (optimal or good). * (number of optimal results/number of laboratories using this buffer) Table 3. Proportion of optimal results for SALL4, as conc. on the 3 main IHC systems* Concentrated antibodies Dako Autostainer Link / Classic Ventana BenchMark XT / Ultra Leica Bond III / Max TRS ph 9.0 TRS ph 6. CC ph 8.5 CC2 ph 6.0 ER2 ph 9.0 ER ph 6.0 mab clone 6E3 3/3** 0/ 4/8 (78%) 0/ 2/3 /2 * Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective systems. ** (number of optimal results/number of laboratories using this buffer) Ready-To-Use antibodies and corresponding systems, product no. 760-4864, Ventana, BenchMark XT, ULTRA: Protocols with optimal result were based on HIER using Cell Conditioning (efficient heating time 32-64 min.), 6-32 min. incubation of the primary Ab and UltraView (760-500) or OptiView (760-700) as detection system. Using these protocol settings 8 of 8 (00%) laboratories produced a sufficient staining result., product no. PM384, Biocare, intellipath: One protocol with an optimal result was based on HIER using Citrate ph 6.0 (Biocare) in a pressure cooker, 45 min. incubation of the primary Ab and MACH4 (M4U534) as detection system.

by a too high concentration of the primary Ab giving a diffuse background staining and aberrant cytoplasmic staining in cells not expressing SALL4. A weak cytoplasmic staining reaction in cells with high level SALL4 expression as neoplastic cells of the seminoma and embryonal carcinoma was accepted. The was the only clone submitted in this run. Optimal results could be obtained both using the concentrated format within a laboratory developed (LD) assay and as ready-to-use (RTU) format. As a concentrate, this clone could be used to produce optimal staining results on all three main IHC systems, see table 3. No special requirements concerning HIER buffer and detection system were needed to provide optimal staining results provided that careful calibration of the primary Ab titer was performed. For example, the, prod. no. CM385, Cell Marque thus provided an optimal result both by a highly sensitive protocol based on HIER 48 min. in CC (Ventana) and a 3-step multimer based detection system (OptiView 760-700, Ventana) but also by a less sensitive protocol based on HIER for 32 min. in CC and a 2-step multimer based system (UltraView 760-500, Ventana). Corresponding RTU systems for the from Ventana and Biocare also provided optimal results. For the Ventana RTU system, optimal results could be obtained both by the official recommendations and by modified protocols adjusting HIER time, incubation time of the primary Ab and/or detection system. Controls Normal testis is recommended as positive tissue control for SALL4. The majority of spermatogonia lining the basement membrane in seminiferous tubules must show an at least weak to moderate but distinct nuclear staining reaction. A dot-like staining of nucleoli in dispersed spermatocytes may be seen. No staining of stromal cells, including Leydig cells, should be seen. Appendix can be used as negative tissue control. No staining reaction should be seen. Fig. a Optimal SALL4 staining of normal testis using the mab clone 6E3 as a concentrate (CM384, Cell Marque) optimally calibrated at a titre of :00, HIER in CC FOR 48 min. and a 3-step multimer based detection system (OptiView 760-700, Ventana). Spermatogonia at the basement membrane of the tubules show a moderate distinct nuclear staining reaction and no background staining is seen. Also compare with Figs. 2a 4a, same protocol. Fig. b Staining for SALL4 of the normal testis assessed as Good. The intensity of the nuclear staining reaction in the spermatogonia is reduced compared to the result obtained in Fig. a same field. However also compare with Figs. 2b and 3b, same protocol. A fully diagnostic sufficient result overall is obtained. The protocol was based on the same mab and titre as in Fig. a, but used with HIER for 32min. in CC and a 2-step multimer based system (UltraView 760-500, Ventana). Nordic Immunohistochemical Quality Control, SALL4 run 43 205 Page 3 of 5

Fig. 2a Optimal staining for SALL4 of the embryonal carcinoma using same protocol as in Fig. a. Virtually all the neoplastic cells show a strong and distinct nuclear staining reaction. No background staining is seen. Fig. 2b Staining for SALL4 of the embryonal carcinoma assessed as Good using same protocol as in Fig. b - same field as in Fig. 2a. The neoplastic cells are demonstrated, but the intensity is reduced. Fig. 3a Optimal staining for SALL4 of the intratubular germ cell neoplasia using same protocol as in Figs. a and 2a. At right virtually all the neoplastic cells show a strong and distinct nuclear staining reaction, whereas normal spermatogonia (left) show a weak to moderate nuclear staining reaction. No background staining is seen. Fig. 3b Staining for SALL4 of the intratubular germ cell neoplasia using same protocol as in Figs. b and 2b. same field as in Fig. 3a. A reduced staining intensity is seen in both the neoplastic cells (right) and normal spermatogonia (left). The overall result was assessed as Good. Nordic Immunohistochemical Quality Control, SALL4 run 43 205 Page 4 of 5

Fig. 4a Optimal staining for SALL4 of the appendix using same protocol as in Figs. a - 3a. No staining reaction is seen. Fig. 4b Insufficient staining reaction for SALL4 of the appendix. A diffuse background staining and aberrant cytoplasmic staining reaction of stromal cells, lymphocytes etc. complicates the interpretation. The result was assessed as Borderline and most likely caused by a too high concentration of the primary. JLL/SN/RR/LE/MV 20-4-205 Nordic Immunohistochemical Quality Control, SALL4 run 43 205 Page 5 of 5